These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38946484)

  • 1. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
    Peterlin P; Saada-Bouzid E; Moskovitz M; Pigneux A; Yuda J; Sinnollareddy M; Henner WR; Chen D; Freise KJ; Leibman RS; Avigdor A; Shimizu T
    Expert Rev Anticancer Ther; 2024 Sep; 24(9):893-904. PubMed ID: 38946484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
    Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.
    Geva R; Vieito M; Ramon J; Perets R; Pedregal M; Corral E; Doger B; Calvo E; Bardina J; Garralda E; Brown RJ; Greger JG; Wu S; Steinbach D; Yao TS; Cao Y; Lauring J; Chaudhary R; Patel J; Patel B; Moreno V
    Cancer Immunol Immunother; 2024 Aug; 73(10):205. PubMed ID: 39105878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
    Leuk Lymphoma; 2024 Sep; 65(9):1281-1291. PubMed ID: 38712673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
    D'Souza A; Shah N; Rodriguez C; Voorhees PM; Weisel K; Bueno OF; Pothacamury RK; Freise KJ; Yue S; Ross JA; Polepally AR; Talati C; Lee S; Jin Z; Buelow B; Vij R; Kumar S
    J Clin Oncol; 2022 Nov; 40(31):3576-3586. PubMed ID: 36029527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
    Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
    Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
    J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
    Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
    Vij R; Nath R; Afar DEH; Mateos MV; Berdeja JG; Raab MS; Guenther A; Martínez-López J; Jakubowiak AJ; Leleu X; Weisel K; Wong S; Gulbranson S; Sheridan JP; Reddy A; Paiva B; Singhal A; San-Miguel JF; Moreau P
    Clin Cancer Res; 2020 May; 26(10):2308-2317. PubMed ID: 31969330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
    Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.